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Introduction
 Nasopharyngeal carcinoma (NPC) is considered as 
one of the rarer cancer forms globally, the incidence of 
NPC has been quoted as 84,000 cases diagnosed annually, 
with an age standardized rate (ASR) of 1.2 per 100,000 for 
both sexes (Ferlay et al., 2008). NPC represents 24th most 
frequently diagnosed cancer form globally and 22nd within 
the developing countries (Jemal et al., 2011). However, the 
distribution of this cancer is highly skewed, the highest 
incidence rates seen in China and Southeast Asian region 
(Cheng et al., 2003). The NPC is most prevalent in Chinese 
and Malaya population and is a leading cause of death 
among Cantonese in Southern China (Guo et al., 2003).  
 The aetiology of NPC is majorly attributed to three risk 
factors namely infection with Epstein-Barr virus (EBV), 
genetic predisposition, and environmental pollutants like 
cigarette smoking, formaldehyde vapours, occupational 
exposure to products of combustion, and cotton dust 
(ICMR bulletin, 2003). Besides, Chinese foods such as 
salt-cured fish and smoke-dried meat which while cooking 
aerosolize carcinogenic nitrosamines that are subsequently 
inhaled may also pose a risk of developing NPC (Guo et 
al., 2003). Despite many individuals being exposed to 
these risk factors, only a minority of them develop NPC. 
This evidence suggests that the inter-individual differences 
in susceptibility can be attributed to the individual’s 
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Abstract
 Background: Studies of associations between genetic polymorphism of glutathione S-transferase M1 (GSTM1) 
and glutathione S-transferase T1 (GSTT1) with risk of nasopharyngeal cancer (NPC) have generated conflicting 
results. Thus, a meta-analysis was performed to clarify the effects of GSTM1 and GSTT1 polymorphisms on the 
risk of developing NPC. Materials and Methods: A literature search in two electronic databases namely PubMed 
and EMBASE up to December 2012 was conducted and eligible papers were finally selected based on the inclusion 
and exclusion criteria. The pooled odds ratio (OR) and presence of heterogeneity and publication bias in those 
studies were evaluated. Results: A total of 9 studies concerning nasopharyngeal cancer were evaluated. Analyses 
of all relevant studies showed increased NPC risk to be significantly associated with the null genotypes of GSTMI 
(OR=1.43, 95%CI 1.24-1.66) and GSTT1 (OR=1.28, 95%CI=1.09-1.51). In addition, evidence of publication bias 
was detected among the studies on GSTM1 polymorphism. Conclusions: This meta-analysis demonstrated the 
GSTM1 and GSTT1 null genotypes are associated with an increased risk of NPC. 
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effectiveness in the detoxification of these chemicals 
which in turn is ascribed to genetic differences.
 Glutathione S-transferases constitute a super-family 
of ubiquitous, multifunctional enzymes, which play a key 
role in cellular detoxification (Ye et al., 2004). GSTM1 
and GSTT1 are known to be highly polymorphic. This 
genetic variation may change an individual’s susceptibility 
to carcinogens and toxins. Homozygous deletions of 
these genes, referred to as GSTM1 null and GSTT1 null, 
respectively, result in lack of enzyme activity and therefore 
have been associated with increased risk for a number of 
cancers including NPC. Though a number of studies have 
focussed on GSTM1 and GSTT1 genetic variation with 
respect to NPC, they have yielded contradictory results. 
Hence, an evidence based quantitative meta-analysis was 
conducted to address this controversy. In addition, the risks 
of developing NPC in relation to GSTM1 and GSTT1 null 
genotypes were also analysed. 
 
Materials and Methods
Selection of studies 
 Studies with information on GSTM1 and GSTT1 
deficiency and the risk of nasopharyngeal cancer were 
identified by bibliographic search in two electronic 
databases; MEDLINE and EMBASE, covering all papers 
published up to December 2012. The search strategy 
Archana Krishna Murthy et al
Asian Pacific Journal of Cancer Prevention, Vol 14, 20131698
used was conducted using the combination of following 
search terms ‘GSTM1, GSTT1, nasopharyngeal cancers, 
polymorphisms, head and neck, neoplasm, carcinoma, 
glutathione’. A manual review of the references cited in 
the selected articles was conducted to retrieve additional 
articles. When several articles were identified for the same 
population, only the most updated source was referred. 
 The following criteria were used for the selection 
of articles for the meta-analysis: 1) Articles explicitly 
describing studies in the association of nasopharyngeal 
cancer with GSTM1 / GSTT1 polymorphisms; 2) Case-
control studies; 3) The nasopharyngeal cancer diagnoses 
and the sources of cases and controls should be stated and 
the studies in which individuals were genotyped by PCR 
technique only; 4) The size of the sample, odds ratios 
(ORs) and their 95% confidence intervals (CIs) or the 
information that can help deduce the results should also 
be stated; 5) Those publications that gave data to allow 
the calculation of such outcomes were also selected. 
 Accordingly, the exclusion criteria used were: 1) 
Design and the definition of the experiments were 
obviously different from those of the selected papers; 2) 
The sample size, source of cases and controls and other 
essential information was not presented; 3) Reviews and 
studies where patients were overlapped. 
Extraction of data 
 Data from the selected articles were extracted and 
entered into STATA, version 10.1 database. The extraction 
was performed by 2 investigators independently. For 
conflicting evaluations, an agreement was reached 
following a discussion. For each study, the author, year 
of publication, country where the study was carried out, 
number, race, and gender of patients and controls, control 
source (hospital based or population based), tumour 
site, and matching of cases and controls were rigorously 
tabulated.
Statistical analysis
 The study-specific crude odds ratio of GSTM1 
and GSTT1 null polymorphisms and nasopharyngeal 
cancers were recalculated for each study along with their 
corresponding 95% confidence intervals. To take into 
account the possibility of heterogeneity across the studies, 
a Chi-square based Q statistic test was performed. If the 
result of the heterogeneity test was p>0.05 indicating the 
absence of heterogeneity, ORs were pooled according 
to fixed – effect model by Mantel-Haenszel method, 
otherwise, the random effect model by DerSimonian and 
Laird Method was used (Cooper and Hedges, 1994). To 
identify publication bias, Egger Regression test was used 
(Egger et al., 1997). 
Results 
 A total of 14 studies regarding GSTM1 and GSTT1 
were identified. Based on the inclusion and exclusion 
criteria, 5 studies were excluded and finally 9 studies 
pertaining to GSTM1 and 5 studies regarding GSTT1 
were selected. A database was established according to 
the extracted information from each article and has been 
listed in Tables 1 and 2.
 Of the included 9 studies, 7 were carried out in 
Asian countries, 1 in America and 1 in Europe. General 
population was used as source of controls in 3 studies 
whereas hospital patients were controls in 2 studies and 
4 did not mention the source of controls. In 3 studies, the 
controls were age and sex-matched with cases and in 2 
studies, controls were matched with cases according to 
the geographical location. In the other 4 studies, matching 
was not mentioned.
Population frequencies
 For GSTM1 polymorphism, the data from the 9 
included case-control studies showed 1294 cases and 1967 
controls, of which 747 cases and 956 controls had the null 
genotype. The frequencies of GSTM1 deficiencies ranged 
from 51.1-64.1% among the cases and 33-55.6% among 
the controls.
 For GSTT1 polymorphism, total study subjects were 
Table 1. Summary of Case-control Studies on GSTM1 Genotype and Nasopharyngeal Cancer
SL.  Author Country Control Source Matching of controls Cases %GSTM1 Controls %GSTM1 OR (95%CI)
No. (Year)    (n/N) deficiency (n/N) deficiency
1 Nazar-Stewart (1999) USA Population healthy Geographical area, age and sex 45/83 54.2 63/142 44.4 1.48 (0.86, 2.56)
2 Da (2002) China Not available None 48/80 60 36/80 45 1.83 (0.98, 3.43)
3 Cheng (2003) Taiwan Population healthy Age, sex and residence 173/314 55.1 169/337 50.1 1.22 (0.90, 1.66)
4 Deng (2004) China Not available None 56/91 61.5 64/135 47.4 1.77 (1.03, 3.05)
5 Liao (2005)  China Not available None 50/80 62.5 32/72 44.4 2.08 (1.09, 3.99)
6 Tiwawech (2005) Thailand Hospital Age 50/78 64.1 74/145 51 1.71 (0.97, 3.02)
7 Bendjemana (2006) France Not available None 24/45 51.1 33/100 33 2.32 (1.13, 4.76)
8 Guo (2008) China Population healthy Geographic region 204/341 59.8 328/590 55.6 1.19 (0.91, 1.56)





































































































Table 2. Summary of Case-control Studies on GSTT1 Genotype and Nasopharyngeal Cancer
SL.  Author (Year) Country Control Source Matching of controls Cases %GSTM1 Controls %GSTM1 OR (95%CI)
No.     (n/N) deficiency (n/N) deficiency
1 Cheng (2003) Taiwan Population healthy Age, sex and residence 160/316 50.6 174/336 51.8 0.96   (0.7, 1.3)
2 Deng (2004) China Not available None 54/91 59.3 55/135 40.7 2.12 (1.24, 3.65)
3 Bendjemana (2006) France Not available None 9/45 20 16/100 15.5 1.31 (0.53, 3.25)
4 Guo (2008) China Population healthy Geographic region 164/338 48.5 269/585 46 1.11 (0.85, 1.45)
5 Jiang (2011) China Hospital Age and sex  120/182 65.9 180/366 49.2 2.00 (1.38, 2.89)
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972 cases and 1522 controls of 48.9% and 40.5% of cases 
and controls respectively had null genotype.
Test of heterogeneity
 The analysis of heterogeneity for all the 9 studies 
of GSTM1 gave the Chi square Q value of 7.57 with 8 
degree of freedom (df) and p=0.477 indicating lack of 
heterogeneity and hence the fixed effect model was used. 
Similarly, the association of GSTT1 null genotype and 
NPC risk, the Chi square Q value was 23.6 with 4 df and 
p=0.100 also suggesting the absence of heterogeneity. 
Therefore the fixed effect model was used for the analysis.
Meta-analysis
 The overall OR for GSTM1 null genotype from the 
included 9 case-control studies was 1.43 (95%CI 1.24-
1.66) and the test for overall effect Z value was 4.95 
(p<0.05) using the fixed effect model (Figure 1). The 
results indicate that GSTM1 null status significantly 
increases the susceptibility to NPC.
 With regard to GSTT1 null genotype, the overall OR 
for the 5 studies was 1.28 (95%CI 1.09-1.51) and the Z 
value was 2.95 (p<0.05) using fixed effect model (Figure 
2). The data implied that GSTT1 null genotype also has 
significant association to NPC.
Publication bias 
 For the diagnosis of publication bias, the Egger’s 
test, when applied, showed an evidence of publication 
bias (p<0.05) for GSTM1 polymorphism. However, for 
GSTT1 polymorphism, p value of Egger’s test was more 
than 0.05, (p=0.415) Thus, the results above suggested that 
publication bias was not evident in this meta-analysis. 
 
Discussion
In the present meta-analysis, risk of development of 
nasopharyngeal cancer in individuals with GSTM1 null 
and GSTT1 null genotype were tabulated and analyzed 
statistically. The outcome of this analysis showed GSTM1 
null status significantly increases the susceptibility 
to NPC which was also true with the GSTT1 null 
status demonstrating significant association with NPC 
development.
Nasopharyngeal cancer (NPC) is an aggressive tumour 
with a high potential for nodal and distant metastasis. 
This tumour is relatively rare in most areas of the world 
but common in Southeast Asia (Lin et al., 2002). The risk 
factors include infection with Epstein-Barr virus (EBV), 
genetic predisposition, and environmental pollutants. 
However development of such a tumour is still not 
clear, presently hypothesised to metabolic activation of 
carcinogenic compounds by Phase I enzymes such as 
cytochrome P4502E1 (CYP2E1) to yield carcinogens 
such as an epoxide form of benzo(a)pyrene and aflatoxin 
that can further interact with host DNA. The epoxide 
thus formed may be detoxified by phase II enzymes, 
particularly GSTs, resulting in cancer inhibition. 
Therefore, NPC susceptibility to carcinogens is dependent 
on the metabolic balance between phase I and phase II 
enzymes customized to individual which meant that 
persons who carried genotypes for high activity of phase I 
enzymes and low activity of phase II enzymes were at high 
risk of developing NPC (Hayashi et al., 1991; Kihara et al., 
1995). Further, human papilloma virus (HPV16) infection 
has been found to reduce GSTM1 enzyme activity and 
GSTM1 mRNA levels in human cervical keratinocytes in 
culture (Chen and Nirunsuksiri, 1999). Hence, the present 
meta-analysis found that individuals with GSTM1 null 
and GSTT1 null genotype showed significant increase in 
the susceptibility to NPC with pooled OR being 1.43 and 
1.28, respectively.
Over the past decades, a large number of meta-
analyses have been done to investigate the association 
between GSTM1 and GSTT1 polymorphisms and various 
Figure 1. Forest Plot of GSTM1 Deficiency and Risk 
of Developing Nasopharyngeal Cancer
Figure 2. Forest Plot of GSTT1 Deficiency and Risk of 
Developing Nasopharyngeal Cancer
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cancers. These include meta-analyses that suggest GSTM1 
deficiency increases the risk of head and neck cancer 
(Hashibe et al., 2003; Ye et al., 2004; Tripathy and Roy, 
2006), cervical cancers (Gao et al., 2011; Liu and Xu, 
2012) and oral cancer (Zhuo et al., 2009). However, a 
number of meta-analyses indicated no marked association 
of GSTM1 null mutations with hepatocellular cancer 
(White et al., 2008), brain tumours (Sima et al., 2012), 
colorectal cancers (Zhao et al., 2012), ovarian cancers 
(Economopoulos et al., 2010), melanoma (Nie et al., 
2011). In this study, the results indicate that null GSTM1 
genotype might increase susceptibility to NPC which 
was in accordance with the evidence-based meta-analysis 
pertaining to GSTM1 and GSTT1 polymorphisms on 
nasopharyngeal cancer by Zhuo et al. (2009). Null 
genotype of GSTT1 has been suggested to associate 
with risks of number of cancers. Marked association of 
GSTT1 deletion with lung cancer (Hosgood et al., 2007), 
gastric cancer (Saadat, 2006), leukaemia (Ye and Song, 
2005), cervical cancers (Gao et al., 2011), breast cancer 
(Chen et al., 2011), bladder cancer (Gong et al., 2012) 
and head and neck cancer (Hashibe et al., 2003) has been 
demonstrated. In this study, the results indicate that null 
GSTT1 genotype might increase susceptibility to NPC 
which was not in line with evidence-based meta-analysis 
of Zhuo et al. (2009) pertaining to GSTM1 and GSTT1 
polymorphisms on nasopharyngeal cancer as the latter 
indicated no association.
In the present meta-analysis, no evidence of 
heterogeneity is observed across studies. However, there 
existed publication bias which was evident in Egger’s 
test in relation to GSTM1 null genotype. In theory, 
publication bias could affect the results of the pooled 
analysis (Vogl et al., 2004). Publication bias can occur if 
studies with insignificant associations or null results are 
less likely to get published than studies with significant 
results, and subsequently the former will not be included 
in the pooled analysis. This would lead to biased results 
and hence the results must be interpreted with caution 
due to the fairly low power when applied to a few meta-
analytically investigated studies. On the other hand, it a 
known fact that published studies are generally of greater 
quality than the unpublished ones (Boccia et al., 2006). 
Hence, if high-quality scored studies are more likely to 
yield valid information than low-quality studies, we can 
conclude that, on the basis of the currently available data, 
an additional slight risk of nasopharyngeal cancer for 
GSTM1 null individuals may exist.
Even though pooling and analyzing individual data 
from original studies has several advantages; the results of 
the present meta-analysis should be interpreted in light of 
a few limitations. Firstly, the study was a meta-analysis of 
case control studies, some of which were hospital-based; 
thus, selection bias might exist. Secondly, the present 
study was based on published articles only; therefore, 
publication bias exists, as suggested from the Egger’s test 
in relation to GSTM1 null genotype and nasopharyngeal 
cancer.
In conclusion, the meta-analysis suggests that GSTM1 
null and GSTT1 null genotype may be associated with 
NPC susceptibility and they may be a potential risk 
factor for NPC. However, future studies with larger 
study populations and more rigorous designs are needed 
to investigate the gene effects and the potential effect of 
environmental factors on nasopharyngeal cancer. 
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